

Table 2 Analysis of correlation between genotypes and related clinical events.

Characteristics	A/A	A/G	P value
Donors	90(47.6%)	99(52.4%)	0.988
Male	61(32.3%)	67(35.4%)	
Female	29(15.3%)	32(16.9%)	
Pre-HCST Patients	63(36.4%)	110(63.6%)	< 0.001
Male	42(24.3%)	63(36.4%)	
Female	21(12.1%)	47(27.2%)	
Donor PB-MAIT ratio (% CD3+T cells)			0.013
≥2.47% (median value)*	33(19.5%)	53(31.4%)	
<2.47%	47 (27.8%)	36 (21.3%)	
Donor BM-MAIT ratio (% CD3+T cells)			0.285
≥3.655% (median value)**	25(22.3%)	31(27.7%)	
<3.655%	29(25.9%)	27(24.1%)	
Acute GVHD	34(18.0%)	40(21.2%)	0.712
Skin aGVHD	25(13.2%)	29(15.3%)	0.818
Gut aGVHD	16(8.5%)	9(4.8%)	0.061
Liver aGVHD	5 (2.6%)	3 (1.6%)	0.389
Acute GVHD grade			
I	8 (4.2%)	21 (11.1%)	0.019
II to IV	27 (14.3%)	19 (10.1%)	0.059
Chronic GVHD	7 (3.7%)	5 (2.6%)	0.319
Relapse	7 (3.7%)	9 (4.8%)	0.746
Death	7 (3.7%)	7 (3.7%)	0.853

* According to the median value of MAIT proportion (% CD3+T cells) in PB of 169 enrolled donors, they were divided into high MAIT proportion group (≥2.47%) and low MAIT proportion group(<2.47%).

** According to the median value of MAIT proportion (% CD3+T cells) in BM of 113 enrolled donors, they were divided into high MAIT proportion group (≥3.655%) and low MAIT proportion group(<3.655%).